Ossianix is a drug discovery & development company that utilises natural single domain antibodies called VNARs. These compact antigen - binding domain have long , finger like projections that preferentially seek out buried binding pockets  and active sites that are typically inaccessible to conventional monoclonal antibodies.  VNARs can be readily formatted to produce  mono, bi & tri  -specific antibodies and Ossianix is developing a product pipeline to targets in inflammation, Oncology, Neuroscience, Metabolic & Muscular disease.

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.